Correlation Between Day One and Editas Medicine

Can any of the company-specific risk be diversified away by investing in both Day One and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Day One and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Day One Biopharmaceuticals and Editas Medicine, you can compare the effects of market volatilities on Day One and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Day One with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of Day One and Editas Medicine.

Diversification Opportunities for Day One and Editas Medicine

0.5

Correlation Coefficient

Day One  Editas Medicine

Very weak diversification

The 3 months correlation between Day and Editas is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding Day One Biopharmaceuticals and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and Day One is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Day One Biopharmaceuticals are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of Day One i.e., Day One and Editas Medicine go up and down completely randomly.

Pair Corralation between Day One and Editas Medicine

Given the investment horizon of 90 days Day One Biopharmaceuticals is expected to generate 0.37 times more return on investment than Editas Medicine. However, Day One Biopharmaceuticals is 2.73 times less risky than Editas Medicine. It trades about -0.21 of its potential returns per unit of risk. Editas Medicine is currently generating about -0.43 per unit of risk. If you would invest  1,432  in Day One Biopharmaceuticals on September 15, 2024 and sell it today you would lose (157.00) from holding Day One Biopharmaceuticals or give up 10.96% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Day One Biopharmaceuticals  vs.  Editas Medicine

Day One Biopharmaceu

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Day One is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Editas Medicine

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Editas Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Day One and Editas Medicine

The main advantage of trading using opposite Day One and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Day One position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.

The idea behind Day One Biopharmaceuticals and Editas Medicine pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.